港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

药明合联

36.750

-0.150-0.41%

成交量：91.25万

成交额：3,355.78万

市值：442.10亿

市盈率：37.66

高：37.200

开：36.900

低：36.400

收：36.900

数据加载中...

总览公司新闻公告

中金：药明合联(02268)订单增长趋势依然强劲维持“跑赢行业”评级

港股生物医药股集体走强，荣昌生物(09995.HK)涨超9%，药明生物(02269.HK)涨超7%，药明合联(02268

《大行》中金升药明合联(02268.HK)目标价至45元订单维持强劲增长

阿斯达克财经

《股市简讯》中国药明合联一度跳涨8%，富瑞上调目标价因在手订单量强劲增长

里昂：升药明合联目标价至47.3港元维持“跑赢大市评级”

异动解读 | 药明合联盘中大涨8%，业绩超预期获多家大行上调目标价

异动解读 | 药明合联盘中大涨8%，业绩亮眼获分析师上调目标价

药明合联高涨逾6% 绩后获多家大行上调目标价

《大行》里昂升药明合联(02268.HK)目标价至47.3元去年业绩符预期

阿斯达克财经

小摩：升药明合联(02268)目标价至46港元评级“增持”

港股异动 | 药明合联(02268)涨超4% 去年纯利同比大增277% 公司订单储备充足

异动解读 | 药明合联盘中大涨5%，交银国际上调目标价至51港元

异动解读 | 药明合联盘中大涨5%，交银国际上调目标价至51港元

【券商聚焦】信达证券：药明合联(02268)订单储备充足今年实现持续高增长确定性较高

交银国际：升药明合联(02268)目标价至51港元行业高景气度+CRDMO模式优势持续驱动业绩强劲增长

药明合联(02268)涨超4% 去年财报乐观绩后获多家大行调升目标价

直击业绩会｜药明合联2024年归母净利润“狂飙”277% 维持今年35%收入增幅预测不变

每日经济新闻

野村：升药明合联目标价至49.76港元去年业绩超预期

野村：升药明合联(02268)目标价至49.76港元去年业绩超预期

药明合联2024年业绩亮眼，净利润同比增长277.2%

每日经济新闻

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02268/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02268","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":36.75,"timestamp":1748229591233,"preClose":36.9,"halted":0,"volume":912500,"delay":0,"floatShares":1203000000,"shares":1203000000,"eps":0.975883815907844,"marketStatus":"交易中","change":-0.15,"latestTime":"05-26 11:20:17","open":36.9,"high":37.2,"low":36.4,"amount":33557842,"amplitude":0.02168,"askPrice":36.75,"askSize":1500,"bidPrice":36.7,"bidSize":15500,"shortable":3,"etf":0,"ttmEps":0.9075353849149752,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1748232000000},"marketStatusCode":2,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":36.9,"openAndCloseTimeList":[[1748223000000,1748232000000],[1748235600000,1748246400000]],"volumeRatio":0.644917,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","floatShares":1203000000,"roa":"7.19%","roe":"17.69%","lyrEps":0.975884,"volumeRatio":0.644917,"shares":1203000000,"dividePrice":0,"high":37.2,"amplitude":0.02168,"preClose":36.9,"low":36.4,"week52Low":14.08,"pbRate":"6.09","psRate":"9.98","week52High":49.5,"institutionHeld":0,"latestPrice":36.75,"committee":0.823529,"eps":0.975883815907844,"divideRate":0,"volume":912500,"delay":0,"ttmEps":0.9075353849149752,"open":36.9,"prevYearClose":30.65,"prevWeekClose":36.9,"prevMonthClose":36.55,"prevQuarterClose":44.4,"fiveDayClose":38.35,"twentyDayClose":36.8,"sixtyDayClose":34.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02268\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522310244","title":"中金：药明合联(02268)订单增长趋势依然强劲 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2522310244","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522310244?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 15:17","pubTimestamp":1743059856,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，药明合联(02268)2024年业绩符合预期，收入同比增长90.8%，净利润增长277.2%，毛利率同比提升4.2个百分点至30.6%，净利率亦提升13个百分点至26.4%，利润能力迅速提升，考虑到订单增长趋势依然强劲，将2025年和2026年经调整净利润预测上调7.4%和12.2%，维持“跑赢行业”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2522314105","title":"港股生物医药股集体走强，荣昌生物(09995.HK)涨超9%，药明生物(02269.HK)涨超7%，药明合联(02268","url":"https://stock-news.laohu8.com/highlight/detail?id=2522314105","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522314105?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 14:39","pubTimestamp":1743057558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["HSTECH","BK0028","LU1064131003.USD","LU2328871848.SGD","LU0823426308.USD","LU0039217434.USD","LU0456827905.SGD","BK1583","BK1574","09995","02268","LU1064130708.USD","LU1820825898.SGD","SG9999014674.SGD","07226","LU1720050803.USD","BK4614","LU1242518857.USD","BK1576","BK0174","LU0417516902.SGD","02269","LU2488822045.USD","LU1688375341.USD","LU0140636845.USD","399441","BK1141","BK1589","LU1997245177.USD","LU0456846285.SGD","LU2125910500.SGD","03347","LU0326950275.SGD","LU0516423174.USD","161726","LU0572944931.SGD","LU2148510915.USD","02359","HSCEI","LU2045819591.USD","688331","YANG","LU0456842615.SGD","603259","300347","LU0052750758.USD","LU0348735423.USD","BK1161","IE00B0JY6N72.USD"],"gpt_icon":0},{"id":"2522313066","title":"《大行》中金升药明合联(02268.HK)目标价至45元  订单维持强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2522313066","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522313066?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 12:58","pubTimestamp":1743051480,"startTime":"0","endTime":"0","summary":"中金发表研报指，药明合联(02268.HK) 2024年业绩符合预期，收入按年增长90.8%，净利润增长277.2%，毛利率按年提升4.2个百分点至30.6%，净利率亦提升13个百分点至26.4%，利润能力迅速提升，考虑到订单增长趋势依然强劲，将2025年和2026年经调整净利润预测上调7.4%和12.2%，目标价上调至45元，维持“跑赢行业”评级。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-27 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104101799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104101799_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1428751/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2522900133","title":"《股市简讯》中国药明合联一度跳涨8%，富瑞上调目标价因在手订单量强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2522900133","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522900133?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 12:26","pubTimestamp":1743049583,"startTime":"0","endTime":"0","summary":"《股市简讯》中国药明合联一度跳涨8%，富瑞上调目标价因在手订单量强劲增长* 从药明生物2269.HK分拆上市的中国药明合联2268.HK周四早盘一度劲升8%，早市收高7.2%。* 美国投行富瑞在报告中表示，将药明合联的目标价由41港元上调至60港元，以反映在手订单量的强劲增长和高可见度；该公司的新加坡生产基地将在2025年底开始生产。* 药明合联今年迄今劲涨46.3%，同期恒生指数.HSI大幅上扬18.3%。* 恒生香港上市生物科技指数.HSHKBIO早盘收涨4.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL3T3QA0CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"gpt_icon":0},{"id":"2522909813","title":"里昂：升药明合联目标价至47.3港元 维持“跑赢大市评级”","url":"https://stock-news.laohu8.com/highlight/detail?id=2522909813","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522909813?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 12:01","pubTimestamp":1743048060,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　里昂发布研报称，药明合联（02268）去年下半年收入和调整后净利润分别同比增长111%和227%，符合市场共识，并超出2025年1月发布的盈利预告。公司预计2025年收入增长35%（指引不变），调整后净利润率与2024年相近。该行将2025财年至2027财年的收入预测小幅调整0-1%，以反映2024年业绩的更新，将目标价从44.3港元上调至47.3港元，维持“跑赢大市评级”。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-03-27/doc-ineraiqt8192147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02268"],"gpt_icon":0},{"id":"1130851258","title":"异动解读 | 药明合联盘中大涨8%，业绩超预期获多家大行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1130851258","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130851258?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 10:54","pubTimestamp":1743044071,"startTime":"0","endTime":"0","summary":"周四盘中，药明合联股价强劲上涨，涨幅达8%，引发市场广泛关注。这波涨势主要受到公司发布的2024年度财报以及多家知名投行上调目标价的推动。这一亮眼的业绩表现超出市场预期，成为推动股价上涨的主要因素之一。花旗将药明合联的目标价从43港元上调至46港元，并给予\"买入\"评级。这些积极的分析报告进一步增强了投资者对药明合联未来发展的信心，推动其股价大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"1162268592","title":"异动解读 | 药明合联盘中大涨8%，业绩亮眼获分析师上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1162268592","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162268592?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 10:54","pubTimestamp":1743044068,"startTime":"0","endTime":"0","summary":"药明合联今日盘中大涨8%，股价表现强劲。这一涨幅主要受到公司发布的2024年度财报及分析师积极评级的推动。根据公司最新发布的财报显示，药明合联2024年度录得纯利10.7亿元人民币，同比大幅增长277.2%，每股盈利89分。多家大型投资银行对药明合联的前景持乐观态度。摩根大通维持\"增持\"评级，同样将目标价上调至46港元。分析师们普遍认为公司2025财年的销售增长预期可能过于保守，并上调了未来几年的销售预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 药明合联盘中大涨8%，业绩亮眼获分析师上调目标价","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"2522399835","title":"药明合联高涨逾6% 绩后获多家大行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2522399835","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522399835?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 10:37","pubTimestamp":1743043066,"startTime":"0","endTime":"0","summary":"该行认为目标略为过于保守。由于药明合联去年的基数较高，且有强劲的积压订单及新订单，将其今年销售额预测上调约20%，并进一步调升2026年打后的长远销售预测23至24%。该行升集团2025至33年的销售额预测20至24%，该行将药明合联目标价升约30%至46港元，维持“增持”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503271038089724a6ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503271038089724a6ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268"],"gpt_icon":0},{"id":"2522828146","title":"《大行》里昂升药明合联(02268.HK)目标价至47.3元  去年业绩符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2522828146","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522828146?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 17:39","pubTimestamp":1742981940,"startTime":"0","endTime":"0","summary":"里昂表示，药明合联(02268.HK) 去年下半年收入和调整后净利润分别按年增长111%和227%，符合市场共识，并超出2025年1月发布的盈利预告。公司预计2025年收入增长35%(指引不变)，调整后净利润率与2024年相近。该行将2025财年至2027财年的收入预测小幅调整0-1%，以反映2024年业绩的更新。该行将目标价从44.3元上调至47.3元。维持“跑赢大市”评级。(ad/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-26 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104104222_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104104222_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1428354/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2522881738","title":"小摩：升药明合联(02268)目标价至46港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2522881738","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522881738?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 16:01","pubTimestamp":1742976086,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，药明合联(02268)去年销售及经调整净利润分别同比增长91%及171%，但管理层仍维持2025财年销售同比增长逾35%的指引。该行认为目标略为过于保守。该行表示，由于药明合联去年的基数较高，且有强劲的积压订单及新订单，将其今年销售额预测上调约20%，并进一步调升2026年往后的长远销售预测23至24%。该行升集团2025至33年的销售额预测20至24%，该行将药明合联目标价升约30%至46港元，维持“增持”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2522902358","title":"港股异动 | 药明合联(02268)涨超4% 去年纯利同比大增277% 公司订单储备充足","url":"https://stock-news.laohu8.com/highlight/detail?id=2522902358","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522902358?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 14:48","pubTimestamp":1742971705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明合联涨超4%，截至发稿，涨4.25%，报41.7港元，成交额1.48亿港元。消息面上，药明合联近期公布2024年业绩，收益约40.52亿元，同比增长90.8%；毛利约12.4亿元，同比增长121.6%；公司拥有人应占纯利约10.7亿元，同比增长277.2%；经调整纯利同比增长184.8%至11.74亿元。从订单储备来看，截至 2024 年底，公司未完成订单总额达到 9.91 亿美元，同比增长 71%，其中新签合同金额与未完成订单增速保持同步，北美地区的未完成订单总额同比增长超 100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02268","SG9999014674.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"1159929750","title":"异动解读 | 药明合联盘中大涨5%，交银国际上调目标价至51港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159929750","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159929750?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 10:32","pubTimestamp":1742956350,"startTime":"0","endTime":"0","summary":"3月26日周三盘中，药明合联股价大涨5%，引发市场关注。这一涨势与交银国际最新发布的研报密切相关。交银国际在研报中上调了药明合联的目标价至51港元，并对公司2025-26年经调整净利润预测上调7-10%。2024年，公司收入和经调整净利润分别同比增长91%和185%，超出此前盈利预告。展望2025年，药明合联管理层指引收入增长35%，并预计利润率将保持稳定，甚至有望进一步提升。这些积极因素共同推动了投资者信心，促使股价上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"1159968125","title":"异动解读 | 药明合联盘中大涨5%，交银国际上调目标价至51港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159968125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159968125?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 10:32","pubTimestamp":1742956346,"startTime":"0","endTime":"0","summary":"周三盘中，药明合联股价大涨5%，引起市场广泛关注。这一涨幅与交银国际最新发布的研报密切相关，该研报上调了药明合联的目标价，并对公司未来发展前景给予积极评价。据悉，交银国际基于药明合联2024年强劲业绩和管理层指引，将公司2025-26年经调整净利润预测上调7-10%，同时将目标价上调至51港元。展望2025年，药明合联管理层指引收入增长35%，利润率有望保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 药明合联盘中大涨5%，交银国际上调目标价至51港元","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"2522851866","title":"【券商聚焦】信达证券：药明合联(02268)订单储备充足 今年实现持续高增长确定性较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2522851866","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522851866?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 10:31","pubTimestamp":1742956289,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达证券发研报指，2024年药明合联 实现营业收入40.52亿元，同比增长91%；实现毛利润12.40亿元，同比增长122%，对应毛利率达到30.6%；实现净利润10.69亿元，同比增长277%，对应净利率达到26.4%；实现经调整净利润11.74亿元，同比增长185%，对应经调整净利率达到29.0%；实现经调整净利润9.92亿元，同比增长171%，对应经调整净利率达到24.5%。该行认为，公司订单储备充足，2025年实现持续高增长的确定性较高。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1955919","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","LU2488822045.USD","601059","SG9999014674.SGD","02268","BK0276"],"gpt_icon":0},{"id":"2522863978","title":"交银国际：升药明合联(02268)目标价至51港元 行业高景气度+CRDMO模式优势持续驱动业绩强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2522863978","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522863978?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 10:24","pubTimestamp":1742955849,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，基于2024年强劲业绩和管理层指引，该行上调药明合联2025-26E经调整净利润预测7-10%、上调DCF目标价至51港元。公司2024年收入增长几乎翻倍、新签53个订单、北美业务快速扩张，体现ADC研发外包行业的持续高景气度和公司CRDMO模式的服务质量优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2522866385","title":"药明合联(02268)涨超4% 去年财报乐观 绩后获多家大行调升目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2522866385","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522866385?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 10:17","pubTimestamp":1742955447,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药明合联 早盘股价走势强劲，截至发稿，报41.75港元，涨4.38%，成交额5605.49万港元。经调整纯利11.74亿元，同比增长184.8%。期内收益40.52亿，同比增加90.8%；毛利12.4亿元，上升121.6%。该行上调2025-26E经调整净利润预测7-10%、上调DCF目标价至51港元。另外，野村表示，药明合联财报反映集团去年下半年的收入及净利润大幅上升，按年分别增111%和447%。认为药明合联的财报相当乐观，重申对其“买入”评级，目标价由42.5港元上调至49.76港元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1955917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"gpt_icon":0},{"id":"2522049569","title":"直击业绩会｜药明合联2024年归母净利润“狂飙”277% 维持今年35%收入增幅预测不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2522049569","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522049569?lang=zh_cn&edition=fundamental","pubTime":"2025-03-25 18:10","pubTimestamp":1742897404,"startTime":"0","endTime":"0","summary":"按照此前药明合联发布的业绩指引，公司今年收入预计将实现35%增长。在3月25日的业绩沟通会上，药明合联对此表示，公司需要确保完成业绩指引，因此目前不会改变这一增幅预测。3月24日晚间，药明合联发布2024年业绩公告。北美地区给药明合联的收入贡献占比也持续提升，从2023年的约40%提升至去年的50%。从利润率来看，药明合联2024年的毛利率和经调整净利润率分别同比提升了4.3个百分点和7.3个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032518111597228ee2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032518111597228ee2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268"],"gpt_icon":0},{"id":"2522483052","title":"野村：升药明合联目标价至49.76港元 去年业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2522483052","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522483052?lang=zh_cn&edition=fundamental","pubTime":"2025-03-25 11:36","pubTimestamp":1742873760,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　野村发布研报称，将药明合联（02268）目标价从42.5港元上调17%至49.76港元，评级为“买入”。考虑到全球对ADC药物的需求旺盛，该行预计2025财年将持续强劲增长。报告指，药明合联2024财年业绩超预期，收入同比增长91%，较机构及该行预测高出15%及19%，利润同比增长277%，较机构及该行预测高出18%及124%。2024年下半年收入及净利增长强劲，同比分别增长111%及447%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-03-25/doc-ineqvvkv9987726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02268"],"gpt_icon":0},{"id":"2522246059","title":"野村：升药明合联(02268)目标价至49.76港元 去年业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2522246059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522246059?lang=zh_cn&edition=fundamental","pubTime":"2025-03-25 11:11","pubTimestamp":1742872293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，野村发布研报称，将药明合联(02268)目标价从42.5港元上调17%至49.76港元，评级为“买入”。考虑到全球对ADC药物的需求旺盛，该行预计2025财年将持续强劲增长。报告指，药明合联2024财年业绩超预期，收入同比增长91%，较机构及该行预测高出15%及19%，利润同比增长277%，较机构及该行预测高出18%及124%。2024年下半年收入及净利增长强劲，同比分别增长111%及447%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1266991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2522039432","title":"药明合联2024年业绩亮眼，净利润同比增长277.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522039432","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522039432?lang=zh_cn&edition=fundamental","pubTime":"2025-03-25 09:15","pubTimestamp":1742865338,"startTime":"0","endTime":"0","summary":"药明合联公布2024年度业绩，营业收入同比增长90.8%，至40.52亿元；净利润同比增长277.2%，至12.4亿元。此前同属药明系的药明康德发布2024年业绩后大涨，其2024年营收同比增长5.2%（剔除去年新冠商业化项目），经调整Non-IFRS归母净利润105.8亿元，净利润率创历史新高。恒生医药ETF（159892）持仓药明康德、药明生物、药明合联等知名标的；近期处于年报密集披露期，医药行业整体业绩呈现良好复苏态势，有望推动估值修复。恒生医药ETF联接（A类：016970，C类：016971）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032509185594bfaf6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032509185594bfaf6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","02268"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02268\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-20","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724117400000,"name":null,"time":"","dateTimestamp":1724083200000,"actualEps":null},{"date":"2024-03-25","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02268\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02268\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.5556,"hold":0.0556,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1743091200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02268\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02268","date":"2025-05-23","current":38.196121,"percent":0.378277,"low":0.407466,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"high":153.052589,"avg":48.388643,"sd":40.865946,"marketCap":44379117053},"quantilePoints":[{"date":"2020-05-29","current":0.450088,"twenty":2.678738,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-06-05","current":0.44683,"twenty":2.666003,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-06-12","current":0.446873,"twenty":2.652949,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-06-19","current":0.446059,"twenty":2.62708,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-06-26","current":0.446464,"twenty":2.610591,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-07-03","current":0.445777,"twenty":2.573756,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-07-10","current":0.441566,"twenty":2.54079,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-07-17","current":0.440865,"twenty":2.474175,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-07-24","current":0.442598,"twenty":2.408815,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-07-31","current":0.440015,"twenty":2.351114,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-08-07","current":0.439541,"twenty":2.260124,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-08-14","current":0.438441,"twenty":0.452125,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-08-21","current":0.436461,"twenty":0.449515,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-08-28","current":0.43308,"twenty":0.448387,"median":7.828992,"eighty":11.018,"marketCap":323186685},{"date":"2020-09-04","current":0.431618,"twenty":0.447817,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-09-11","current":0.431156,"twenty":0.447535,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-09-18","current":0.427016,"twenty":0.447373,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-09-25","current":0.430436,"twenty":0.447153,"median":7.826865,"eighty":11.015587,"marketCap":323186685},{"date":"2020-09-30","current":0.428392,"twenty":0.446995,"median":7.824737,"eighty":11.013173,"marketCap":323186685},{"date":"2020-10-09","current":0.422312,"twenty":0.446839,"median":7.815551,"eighty":11.015587,"marketCap":323186685},{"date":"2020-10-16","current":0.422486,"twenty":0.446689,"median":7.778238,"eighty":11.015587,"marketCap":323186685},{"date":"2020-10-23","current":0.421832,"twenty":0.446509,"median":7.763554,"eighty":11.013173,"marketCap":323186685},{"date":"2020-10-30","current":0.421767,"twenty":0.446296,"median":7.728277,"eighty":11.015587,"marketCap":323186685},{"date":"2020-11-06","current":0.416892,"twenty":0.446096,"median":7.681665,"eighty":11.015587,"marketCap":323186685},{"date":"2020-11-13","current":0.416542,"twenty":0.445828,"median":7.62168,"eighty":11.015587,"marketCap":323186685},{"date":"2020-11-20","current":0.413946,"twenty":0.445667,"median":7.588964,"eighty":11.015587,"marketCap":323186685},{"date":"2020-11-27","current":0.414916,"twenty":0.445574,"median":7.400318,"eighty":11.015587,"marketCap":323186685},{"date":"2020-12-04","current":0.411952,"twenty":0.44527,"median":7.31626,"eighty":11.015587,"marketCap":323186685},{"date":"2020-12-11","current":0.41294,"twenty":0.44498,"median":7.224146,"eighty":11.015587,"marketCap":323186685},{"date":"2020-12-18","current":0.412272,"twenty":0.444321,"median":7.177259,"eighty":11.047512,"marketCap":323186685},{"date":"2020-12-24","current":0.411847,"twenty":0.443892,"median":6.957959,"eighty":11.047512,"marketCap":323186685},{"date":"2020-12-31","current":0.411678,"twenty":0.44363,"median":6.764797,"eighty":11.047512,"marketCap":323186685},{"date":"2021-01-08","current":0.408416,"twenty":0.443491,"median":6.650061,"eighty":11.067383,"marketCap":323186685},{"date":"2021-01-15","current":0.408583,"twenty":0.442598,"median":6.55329,"eighty":11.072351,"marketCap":323186685},{"date":"2021-01-22","current":0.408755,"twenty":0.442234,"median":6.512372,"eighty":11.072351,"marketCap":323186685},{"date":"2023-11-17","current":130.035431,"twenty":0.435785,"median":0.444801,"eighty":2.787891,"marketCap":32996488000},{"date":"2023-11-24","current":133.579843,"twenty":0.435785,"median":0.444801,"eighty":2.810425,"marketCap":34174934000},{"date":"2023-12-01","current":147.707211,"twenty":0.435785,"median":0.444801,"eighty":2.852893,"marketCap":37945961200},{"date":"2023-12-08","current":132.646927,"twenty":0.435785,"median":0.444801,"eighty":2.935117,"marketCap":33939244800},{"date":"2023-12-15","current":138.75437,"twenty":0.435785,"median":0.444801,"eighty":3.039251,"marketCap":35706913800},{"date":"2023-12-22","current":153.052589,"twenty":0.435785,"median":0.444801,"eighty":3.172504,"marketCap":39360096400},{"date":"2023-12-29","current":145.85951,"twenty":0.435785,"median":0.444801,"eighty":3.326638,"marketCap":37710272000},{"date":"2024-01-05","current":142.305018,"twenty":0.435785,"median":0.444801,"eighty":3.599996,"marketCap":36531826000},{"date":"2024-01-12","current":138.558869,"twenty":0.435785,"median":0.444801,"eighty":3.622774,"marketCap":35589069200},{"date":"2024-01-19","current":141.046625,"twenty":0.435785,"median":0.444801,"eighty":3.635946,"marketCap":36178292200},{"date":"2024-01-26","current":116.23004,"twenty":0.435785,"median":0.444801,"eighty":3.642902,"marketCap":29696839200},{"date":"2024-02-02","current":82.111439,"twenty":0.435785,"median":0.444801,"eighty":3.654128,"marketCap":20952769880},{"date":"2024-02-09","current":67.278987,"twenty":0.435825,"median":0.445043,"eighty":3.68657,"marketCap":17252449440},{"date":"2024-02-16","current":66.713097,"twenty":0.435798,"median":0.44487,"eighty":3.704054,"marketCap":17111035920},{"date":"2024-02-23","current":82.124312,"twenty":0.435798,"median":0.44487,"eighty":3.728385,"marketCap":20952769880},{"date":"2024-03-01","current":86.135235,"twenty":0.435812,"median":0.444939,"eighty":3.767614,"marketCap":21989802360},{"date":"2024-03-08","current":96.662972,"twenty":0.435812,"median":0.444939,"eighty":3.804363,"marketCap":24688443700},{"date":"2024-03-15","current":72.134287,"twenty":0.435812,"median":0.444939,"eighty":3.87411,"marketCap":18407326520},{"date":"2024-03-22","current":82.739174,"twenty":0.435812,"median":0.444939,"eighty":3.907844,"marketCap":21094183400},{"date":"2024-03-28","current":70.236298,"twenty":0.435812,"median":0.444939,"eighty":3.924107,"marketCap":21565561800},{"date":"2024-04-05","current":69.514463,"twenty":0.435772,"median":0.444721,"eighty":3.932321,"marketCap":21329872600},{"date":"2024-04-12","current":72.929575,"twenty":0.435785,"median":0.444801,"eighty":3.970214,"marketCap":22390474000},{"date":"2024-04-19","current":66.691535,"twenty":0.435785,"median":0.444801,"eighty":4.01279,"marketCap":20457822560},{"date":"2024-04-26","current":78.851628,"twenty":0.435812,"median":0.444939,"eighty":62.837086,"marketCap":24158143000},{"date":"2024-05-03","current":79.483533,"twenty":0.435812,"median":0.444939,"eighty":66.70016,"marketCap":24334909900},{"date":"2024-05-10","current":73.189732,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":22461180760},{"date":"2024-05-17","current":65.221538,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19986444160},{"date":"2024-05-24","current":58.278715,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17818103520},{"date":"2024-05-31","current":59.948577,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":18347300940},{"date":"2024-06-07","current":58.299117,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17820354960},{"date":"2024-06-14","current":64.156468,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19592809620},{"date":"2024-06-21","current":70.500097,"twenty":0.435812,"median":0.444939,"eighty":69.593748,"marketCap":21485024730},{"date":"2024-06-28","current":68.013259,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":20718557850},{"date":"2024-07-05","current":61.893714,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":18850294830},{"date":"2024-07-12","current":63.530585,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":19377240810},{"date":"2024-07-19","current":56.933019,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17365265250},{"date":"2024-07-26","current":56.800526,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17389217340},{"date":"2024-08-02","current":69.358964,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":21221551740},{"date":"2024-08-09","current":72.710245,"twenty":0.435812,"median":0.444939,"eighty":70.597189,"marketCap":22395204150},{"date":"2024-08-16","current":74.003491,"twenty":0.435812,"median":0.444939,"eighty":70.930659,"marketCap":22802389680},{"date":"2024-08-23","current":35.050376,"twenty":0.435812,"median":0.44524,"eighty":71.736965,"marketCap":22742129354},{"date":"2024-08-30","current":36.779427,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":24024219892},{"date":"2024-09-06","current":36.193339,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":23652773101},{"date":"2024-09-13","current":36.950123,"twenty":0.435812,"median":0.445611,"eighty":71.736965,"marketCap":24084130665},{"date":"2024-09-20","current":36.912594,"twenty":0.435798,"median":0.445732,"eighty":71.812082,"marketCap":24203952211},{"date":"2024-09-27","current":41.596291,"twenty":0.435798,"median":0.446064,"eighty":71.812082,"marketCap":27439133942},{"date":"2024-10-04","current":49.267448,"twenty":0.435798,"median":0.446181,"eighty":71.812082,"marketCap":32351817312},{"date":"2024-10-10","current":43.61955,"twenty":0.435812,"median":0.446472,"eighty":71.736965,"marketCap":28457617080},{"date":"2024-10-18","current":43.201999,"twenty":0.435798,"median":0.446694,"eighty":71.812082,"marketCap":28038241670},{"date":"2024-10-25","current":43.020102,"twenty":0.435798,"median":0.446852,"eighty":71.812082,"marketCap":27918420124},{"date":"2024-11-01","current":41.699543,"twenty":0.435798,"median":0.446999,"eighty":71.812082,"marketCap":27079669305},{"date":"2024-11-08","current":47.130705,"twenty":0.435852,"median":0.447279,"eighty":71.812082,"marketCap":30374761809},{"date":"2024-11-15","current":46.740281,"twenty":0.435852,"median":0.44753,"eighty":71.812082,"marketCap":29895475627},{"date":"2024-11-22","current":46.01742,"twenty":0.435852,"median":0.447785,"eighty":71.812082,"marketCap":29416189444},{"date":"2024-11-29","current":51.670123,"twenty":0.435852,"median":0.448371,"eighty":71.812082,"marketCap":33010835812},{"date":"2024-12-06","current":54.048034,"twenty":0.435852,"median":0.449445,"eighty":71.812082,"marketCap":34448694360},{"date":"2024-12-13","current":58.707371,"twenty":0.435852,"median":0.45138,"eighty":71.812082,"marketCap":37384322227},{"date":"2024-12-20","current":60.54506,"twenty":0.435852,"median":35.016583,"eighty":71.812082,"marketCap":38342894592},{"date":"2024-12-27","current":58.22519,"twenty":0.435852,"median":35.863906,"eighty":71.812082,"marketCap":36845125272},{"date":"2025-01-03","current":57.033249,"twenty":0.435852,"median":36.241161,"eighty":71.812082,"marketCap":36126195998},{"date":"2025-01-10","current":62.66188,"twenty":0.435852,"median":36.730689,"eighty":71.812082,"marketCap":39541110048},{"date":"2025-01-17","current":54.642634,"twenty":0.436361,"median":37.212991,"eighty":71.812082,"marketCap":34508605132},{"date":"2025-01-24","current":54.868028,"twenty":0.436606,"median":39.470644,"eighty":71.812082,"marketCap":34868069769},{"date":"2025-01-28","current":52.331181,"twenty":0.436643,"median":41.238065,"eighty":71.736965,"marketCap":33430211222},{"date":"2025-02-07","current":57.910706,"twenty":0.437089,"median":42.380717,"eighty":71.8872,"marketCap":36785214499},{"date":"2025-02-14","current":56.82028,"twenty":0.437089,"median":43.020102,"eighty":71.8872,"marketCap":36006374452},{"date":"2025-02-21","current":70.802488,"twenty":0.437089,"median":44.139364,"eighty":71.8872,"marketCap":45112811918},{"date":"2025-02-28","current":60.65941,"twenty":0.437089,"median":45.078416,"eighty":71.8872,"marketCap":38522626910},{"date":"2025-03-07","current":67.088057,"twenty":0.437583,"median":46.607669,"eighty":71.962317,"marketCap":42776291779},{"date":"2025-03-14","current":72.98104,"twenty":0.438098,"median":47.703312,"eighty":71.990989,"marketCap":46550670465},{"date":"2025-03-21","current":80.244903,"twenty":0.438098,"median":49.592986,"eighty":72.978175,"marketCap":51163799971},{"date":"2025-03-28","current":47.906694,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":54840613248},{"date":"2025-04-03","current":43.121995,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":49380552191},{"date":"2025-04-11","current":35.581021,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":40380451549},{"date":"2025-04-17","current":33.597127,"twenty":0.4381,"median":49.700845,"eighty":72.980467,"marketCap":38220427395},{"date":"2025-04-25","current":39.226609,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44663120338},{"date":"2025-05-02","current":40.829264,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":46586700218},{"date":"2025-05-09","current":38.818219,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44603008467},{"date":"2025-05-16","current":39.608151,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":45882474676},{"date":"2025-05-23","current":38.196121,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44379117053}],"updateTime":1748191405361}}}